Pluristem (PSTI) - Total Assets
Based on the latest financial reports, Pluristem (PSTI) holds total assets worth ILA79.13 Million ILA (≈ $212.14K USD) as of March 2022. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Pluristem shareholders equity for net asset value and shareholders' equity analysis.
Pluristem - Total Assets Trend (2014–2021)
This chart illustrates how Pluristem's total assets have evolved over time, based on quarterly financial data.
Pluristem - Asset Composition Analysis
Current Asset Composition (June 2021)
Pluristem's total assets of ILA79.13 Million consist of 72.0% current assets and 28.0% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 33.4% |
| Accounts Receivable | ILA1.49 Million | 1.6% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA2.23 Million | 2.4% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2014–2021)
This chart illustrates how Pluristem's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PSTI market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pluristem's current assets represent 72.0% of total assets in 2021, a decrease from 83.7% in 2014.
- Cash Position: Cash and equivalents constituted 33.4% of total assets in 2021, up from 6.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 2.4% of total assets.
Pluristem Competitors by Total Assets
Key competitors of Pluristem based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Pluristem - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.22 | 5.02 | 5.36 |
| Quick Ratio | 8.22 | 5.02 | 5.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA56.49 Million | ILA39.90 Million | ILA23.60 Million |
Pluristem - Advanced Valuation Insights
This section examines the relationship between Pluristem's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.90 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | 42.7% |
| Total Assets | ILA93.54 Million |
| Market Capitalization | $65.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pluristem's assets below their book value (0.70x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pluristem's assets grew by 42.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pluristem (2014–2021)
The table below shows the annual total assets of Pluristem from 2014 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-06-30 | ILA93.54 Million ≈ $250.77K |
+42.74% |
| 2020-06-30 | ILA65.53 Million ≈ $175.69K |
+109.30% |
| 2019-06-30 | ILA31.31 Million ≈ $83.94K |
-19.64% |
| 2018-06-30 | ILA38.96 Million ≈ $104.45K |
+3.80% |
| 2017-06-30 | ILA37.53 Million ≈ $100.63K |
-18.30% |
| 2016-06-30 | ILA45.94 Million ≈ $123.17K |
-32.59% |
| 2015-06-30 | ILA68.16 Million ≈ $182.72K |
-7.93% |
| 2014-06-30 | ILA74.02 Million ≈ $198.45K |
-- |
About Pluristem
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase I… Read more